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Abstract
Background: The triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio has been
reported to be as closely correlated with insulin resistance as is the fasting serum insulin
concentration (FSI), and therefore it is seen as a clinically useful way to identify the concomitant
presence of insulin resistance and dyslipidemia. However, conflicting findings exist for the
association of the TG/HDL-C ratio with FSI by race/ethnicity.
Methods: The associations of FSI concentration, serum triglyceride concentrations, and HDL-C
were analyzed using log-binomial regression analyses and receiver operating characteristic (ROC)
curve analysis among nondiabetic adults (n = 2652, aged t 20 years, 51.2% men) in the United
States.
Results: After adjustment for potential confounding effects, the prevalence ratio of
hyperinsulinemia was 2.16 (95% confidence interval [CI], 1.74 to 2.08) when using a single cutoff
point of 3.5, and 2.23 (95% CI, 1.83 to 2.72) when using race/ethnicity-specific cutoff points of 3.0
for non-Hispanic whites and Mexican Americans and 2.0 for non-Hispanic blacks for the TG/HDL-
C ratio. The area under the ROC curve of the TG/HDL-C ratio for predicting hyperinsulinemia
was 0.77 (95% CI, 0.74 to 0.79), 0.75 (95% CI, 0.69 to 0.77), and 0.74 (95% CI, 0.69 to 0.76) for
non-Hispanic whites, non-Hispanic blacks, and Mexican Americans, respectively.
Conclusion: There was a significant association between the TG/HDL-C ratio and FSI among
three major racial/ethnic groups in the United States. Our results add further support to the notion
that the TG/HDL-C ratio may be a clinically simple and useful indicator for hyperinsulinemia among
nondiabetic adults regardless of race/ethnicity.
Background
The prevalence of hyperinsulinemia has increased by
about 35% among nondiabetic adults in the past decade
in the United States [1]. Insulin resistance has been pro-
posed as an underlying cause of type 2 diabetes and the
metabolic syndrome [2,3] and has been found to be asso-
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ciated with increased risk for cardiovascular diseases
[2,4,5]. The availability of relatively simple measures to
identify apparently healthy people who are sufficiently
insulin resistant to be at increased risk of developing type
2 diabetes, cardiovascular disease, and the numerous
other clinical syndromes that occur with increased fre-
quency in insulin-resistant persons would be of signifi-
cant clinical benefit [6-8].
The triglyceride to high-density lipoprotein cholesterol
(TG/HDL-C) concentration ratio has been reported to be
as closely related to insulin resistance as is the fasting
plasma insulin concentration [9,10], a commonly used
surrogate estimate of insulin resistance. Previous studies
have demonstrated that fasting insulin was highly corre-
lated with homeostasis model assessment (HOMA) and
quantitative insulin sensitivity check index (QUICKI)
(correlation coefficients >0.95) of insulin resistance
among nondiabetic individuals [11-13]. In contrast to
measures of lipid and lipoprotein concentrations, there
has been no attempt to standardize assays of insulin con-
centration to date. Thus, it seemed possible that use of the
TG/HDL-C ratio, based on commonly available and
standardized measurements, could help clinicians iden-
tify persons who were not only insulin resistant but also
displayed the characteristic dyslipidemia of people with
this defect in insulin action [9,10]. The relationship
between the TG/HDL-C ratio and a direct measure of insu-
lin resistance was first reported among 258 overweight or
obese adults, of whom 87% were non-Hispanic whites
[9]. This association has been replicated in a larger clini-
cally based sample that represented the general popula-
tion [10]. Elsewhere, in a study in an East African
population, the TG/HDL-C ratio was found to be signifi-
cantly associated with insulin resistance as measured by
HOMA [14]. In contrast, recent studies have reported that
the triglyceride or triglycerides/HDL-C ratio was not sig-
nificantly associated with insulin resistance in black
adults [15] and adolescents [16].
In previous studies, black males have had lower triglycer-
ide concentrations and higher HDL-C concentrations
than white males, while versus white females, black
females have had similar or lower triglyceride concentra-
tions and comparable HDL-C concentrations [17]. Else-
where, Mexican American males were found to have
higher fasting serum insulin (FSI) concentrations than
white or black males, while adult black or Mexican Amer-
ican females were reported to have higher FSI concentra-
tions than their white counterparts [18]. In US youth aged
12–17 years, there were no significant variations by race/
ethnicity among males, while black females had higher
FSI concentrations than white or Mexican American
females [19].
Because of racial/ethnic variations in triglyceride, HDL-C,
and FSI concentrations, the association of the TG/HDL-C
ratio with FSI may differ by race/ethnicity. To the best of
our knowledge, no studies have investigated the possibil-
ity of such differences. Thus, the goal of this study was to
use a nationally representative sample to determine
whether the association of triglyceride, HDL-C, and the
TG/HDL-C ratio with the FSI may differ between non-His-
panic whites, non-Hispanic blacks, and Mexican Ameri-
cans.
Methods
Study design and participants
In the National Health and Nutrition Examination Survey
(NHANES) conducted during 1999–2002, the samples
were recruited using a multistage, stratified sampling
design to represent the noninstitutionalized civilian US
population. After being interviewed at home, participants
were invited to attend the mobile examination center,
where they provided a blood sample and were examined.
Details about the survey may be found elsewhere [20,21].
We limited the analyses to men and nonpregnant women
aged t 20 years who attended the morning medical exam-
ination and had fasted t 8 hours. All participants who had
a positive history of diabetes or currently had a fasting glu-
cose concentration t 126 mg/dL (7.0 mmol/L) were
excluded. Participants of other races and ethnicities were
excluded because of small samples. The final sample (n =
2652; unweighted: 51.2% men, 56.8% non-Hispanic
whites, 18.1% non-Hispanic blacks, and 25.1% Mexican
Americans; weighted: 49.4% men, 82.2% non-Hispanic
whites, 10.5% non-Hispanic blacks, and 7.3% Mexican
Americans) represents nondiabetic adults aged t 20 years
in the United States.
Procedures
Serum specimens were frozen at <-70°C, shipped on dry
ice, and stored at <-70°C until analysis. All insulin assays
were performed at the same laboratory of the University
of Missouri at Columbia. FSI concentration was measured
using a radioimmunoassay kit from Pharmacia Diagnos-
tics AB (Uppsala, Sweden). The cross-reactivity of Pharma-
cia insulin antibody with proinsulin is approximately
40%. Quality control procedures followed modified
Westgard rules and included both within- and between-
assay quality control procedures using Levy-Jennings
chart plots for means and ranges with monitoring of
trend. The overall coefficients of variation ranged from
3.3% to 5.4% in NHANES 1999–2002. Details of the lab-
oratory procedures for insulin assay are found elsewhere
[20,21]. Plasma glucose concentration was measured
using an enzymatic reaction. Serum triglyceride concen-
trations were measured enzymatically after hydrolyzation
to glycerol. HDL-C was measured after the precipitation of
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other lipoproteins with a heparin-manganese chloride
mixture. C-reactive protein (CRP) concentrations were
quantified by latex-enhanced nephelometry (N High Sen-
sitivity CRP assay) on a BN II nephelometer (Dade
Behring Inc., Deerfield IL).
Waist circumference was measured to the nearest 0.1 cm
with a steel measuring tape at the high point of the iliac
crest at minimal respiration. Body mass index [BMI =
weight (kg)/height (m)2] was calculated using measured
weight and height, and BMIs were categorized into three
groups (1: <25, 2: 25 to 29.9, and 3: t 30) according to
World Health Organization criteria [22]. Up to four blood
pressure readings were obtained in the mobile examina-
tion center; for participants with three or four the average
of the last two was used to establish blood pressure status;
if there were only two measurements, the second one was
used (a few participants had just one measurement).
Statistical analyses
We assessed the distribution and normality of continuous
variables and performed logarithmic transformation for
the FSI, triglycerides, HDL-C, and the triglycerides/HDL-C
ratio to approximate a normal distribution. Multiple lin-
ear regression models were performed to assess the associ-
ation of triglycerides, HDL-C, and the triglycerides/HDL-
C ratio with FSI while adjusting for potential confounders
including age, education, poverty-income ratio, smoking
status, systolic blood pressure, CRP, and waist circumfer-
ence. Standardized regression coefficients were estimated
to facilitate comparisons across variables with different
metric scales.
We defined hyperinsulinemia using the 75th percentile
cutoff values of the FSI concentration among nondiabetic
participants in NHANES 1999–2002 according to the sug-
gestion of the European Group for the Study of Insulin
Resistance [23]. The area under the receiver-operating
characteristic (ROC) curve was used to examine the pre-
dictive value of triglyceride, HDL-C, and the triglycerides/
HDL-C ratio for hyperinsulinemia by race/ethnicity sepa-
rately. Values for the area under the ROC curve of 0.5, t
0.7 but < 0.8, t 0.8 but < 0.9, and t 0.9 have been sug-
gested as reflecting the following levels of discrimination:
none, acceptable, excellent, and outstanding [24]. The
Youden index was calculated using the following formula:
sensitivity + specificity – 1 [25], and the maximum value
of the Youden index corresponded to the optimal cutoff
point [26]. The areas under the ROC curve were estimated
and compared between racial/ethnic subgroups using the
SAS macros that were created specifically to account for
the sampling weights of survey data [27]. In addition, we
estimated the prevalence of hyperinsulinemia associated
with the proposed TG/HDL-C ratio t 3.5 [10] stratified by
BMI and race/ethnicity. The prevalence ratio (PR) and
95% confidence interval (CI) were estimated using the
log-binomial regression analysis [28]. An D of 0.05 was
used as a statistical significance level for two-sided tests.
All analyses were conducted using SAS (version 9.1) and
SUDAAN software (Release 9.0, Research Triangle Insti-
tute, Research Triangle Park, NC) to account for the com-
plex sampling design.
Results
The distribution of triglycerides, HDL-C, and TG/HDL-C
ratio appeared to be similar between men and women,
but different between racial/ethnic groups (Figure 1).
Pearson correlation coefficients were -0.41, 0.93, and -
0.71 for triglycerides versus HDL-C, triglycerides versus
the TG/HDL-C ratio, and HDL-C versus the TG/HDL-C
ratio, respectively.
Among men, non-Hispanic blacks had a lower mean trig-
lyceride concentration, a higher mean HDL-C concentra-
tion, and a lower TG/HDL-C ratio than both non-
Hispanic whites and Mexican Americans (Table 1). In
contrast, Mexican American men had a higher FSI concen-
tration than their non-Hispanic white and non-Hispanic
black counterparts. Among women, non-Hispanic blacks
had a lower mean triglyceride concentration and lower
TG/HDL-C ratio than both non-Hispanic whites and Mex-
ican Americans. Mexican Americans, in contrast, had a
lower mean HDL-C concentration than both non-His-
panic whites and non-Hispanic blacks. Non-Hispanic
blacks and Mexican Americans had a higher mean FSI
than non-Hispanic whites.
After adjustment for potential confounding effects, trig-
lycerides, HDL-C, and the TG/HDL-C ratio were signifi-
cantly associated with FSI in the three racial/ethnic groups
(Table 2). No significant difference in the regression coef-
ficients between any two racial/ethnic groups was
detected (all P > 0.017 with Bonferroni adjustment).
There was no significant interaction between race/ethnic-
ity and triglycerides, HDL-C, or the TG/HDL-C ratio (P
ranged from 0.22 to 0.98) on the FSI in the combined
data.
The 75th percentile cutoff point for FSI was 78.77 pmol/L
(13.131 uU/mL) among nondiabetic people in NHANES
1999–2002. The area under the ROC curve of the TG/
HDL-C ratio (AUC = 0.75; 95% CI, 0.73–0.78) was larger
than that of triglyceride (AUC = 0.72; 95% CI, 0.69–0.74;
P < 0.0001) or HDL-C (AUC = 0.72; 95% CI, 0.69–0.74;
P = 0.0007) alone for the prediction of hyperinsulinemia
(Figure 2). According to the maximum value of the
Youden index, the optimal cutoff point for the TG/HDL-C
ratio was 1.2 in mmol/L unit (or equivalent to 3 in mg/dl
unit) for both non-Hispanic whites and Mexican Ameri-
cans and 0.9 in mmol/L unit (or equivalent to 2 in mg/dl
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Distribution of triglycerides, HDL-C, and the TG/HDL-C ratio in original metric scale by sex and race/ethnicityFigure 1
Distribution of triglycerides, HDL-C, and the TG/HDL-C ratio in original metric scale by sex and race/ethnicity. A, triglycerides 
in men; B, triglycerides in women; C, HDL-C in men; D, HDL-C in women; E, the TG/HDL-C ratio in men; and F, the TG/
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unit) for non-Hispanic blacks. The corresponding sensi-
tivity and specificity were 70.6% and 71.0% in non-His-
panic whites, 61.6% and 77.4% in non-Hispanic blacks,
and 64.1% and 71.1% in Mexican Americans.
The unadjusted prevalence of hyperinsulinemia was more
than doubled among people with TG/HDL-C t 3.5 (or the
new cutoff point) than those with TG/HDL-C < 3.5 (or the
new cutoff point); and this pattern was consistent across
the three BMI categories and the three racial/ethnic groups
(Table 3). Using the cutoff points of 3.0 for non-Hispanic
white and Mexican Americans and 2.0 for non-Hispanic
blacks yielded lower prevalence rates of hyperinsuline-
mia, but larger prevalence ratios compared to the cutoff
point of 3.5 among non-Hispanic blacks and Mexican
Americans, and among people with a BMI <25 or between
25 and 29 kg/m2. There was a significant interaction
between the TG/HDL-C ratio and BMI for both sets of cut-
Table 2: Metric and standardized regression coefficients of triglycerides, HDL-C, and the TG/HDL-C ratio on FSI by sex and race/
ethnicity
Non-Hispanic White (NHW) Non-Hispanic Black (NHB) Mexican American (MA) P-value‡







Men n = 770 n = 243 n = 346
Triglycerides 
(mmol/L)
0.22 0.03 0.25 0.30 0.06 0.23 0.28 0.06 0.31 0.13 0.63 0.29 0.22
HDL-C (mmol/L) -0.51 0.07 -0.24 -0.45 0.12 -0.20 -0.46 0.10 -0.21 0.98 0.88 0.94 0.98
TG/HDL-C ratio 0.19 0.02 0.27 0.24 0.04 0.25 0.22 0.04 0.31 0.14 0.75 0.32 0.27
Women n = 737 n = 236 n = 320
Triglycerides 
(mmol/L)
0.26 0.07 0.26 0.28 0.08 0.24 0.44 0.05 0.42 0.67 0.03 0.05 0.23
HDL-C (mmol/L) -0.46 0.07 -0.25 -0.32 0.11 -0.18 -0.61 0.12 -0.28 0.72 0.31 0.26 0.60
TG/HDL-C ratio 0.24 0.05 0.30 0.21 0.05 0.24 0.34 0.03 0.40 0.55 0.05 0.05 0.26
HDL = high-density lipoprotein; FSI = fasting serum insulin. W = non-Hispanic white, B = non-Hispanic black, M = Mexican American.
* Em – metric regression coefficient. SE = standard error.
† Es – standardized regression coefficient. Em and Es were adjusted for age, education attainment, poverty-income ratio, smoking, systolic blood pressure, 
C-reactive protein, and waist circumference. All individual regression coefficients were significant at D = 0.05 level.
‡ Significance level with Bonferroni adjustment for multiple comparisons is 0.05/3 | 0.017.
§Interaction between race/ethnicity and TG/HDL-C ratio.
Table 1: Geometric means of triglycerides, HDL-C, the TG/HDL-C ratio, and FSI by sex and race/ethnicity
Non-Hispanic White (NHW) Non-Hispanic Black (NHB) Mexican American (MA) P value†






Men N = 770 N = 243 N = 346
Triglycerides (mmol/L)‡ 1.46 1.38 1.54 1.03 0.95 1.12 1.46 1.31 1.63 <0.001 0.975 <0.001
HDL-C (mmol/L)§ 1.13 1.11 1.16 1.28 1.24 1.33 1.12 1.09 1.15 <0.001 0.588 <0.001
TG/HDL-C ratio 1.29 1.20 1.38 0.81 0.73 0.90 1.30 1.14 1.49 <0.001 0.863 <0.001
FSI (pmol/L)|| 58.0 55.3 60.9 56.4 52.4 60.7 69.4 65.1 73.8 0.494 <0.001 <0.001
Women N = 737 N = 236 N = 320
Triglycerides (mmol/L) 1.27 1.23 1.32 0.94 0.88 1.00 1.30 1.21 1.40 <0.001 0.671 <0.001
HDL-C (mmol/L) 1.43 1.39 1.46 1.39 1.34 1.44 1.28 1.24 1.31 0.287 <0.001 <0.001
TG/HDL-C ratio 0.89 0.85 0.94 0.67 0.62 0.73 1.02 0.93 1.11 <0.001 0.030 <0.001
FSI (pmol/L) 51.1 48.9 53.4 67.8 62.7 73.3 67.9 61.6 74.9 <0.001 <0.001 0.966
HDL = high-density lipoprotein; FSI = fasting serum insulin; CI = confidence interval. * Weighted unadjusted geometric means.
† P-values indicate the significance of the differences in the means of triglycerides, HDL-C, the TG/HDL-C ratio, and FSI between two racial/ethnic 
groups. NHW = non-Hispanic white, NHB = non-Hispanic black, MA = Mexican American. Significance level with Bonferroni adjustment for multiple 
comparisons is 0.05/3 | 0.017.
‡ To convert triglyceride concentration to mg/dl, divide concentration in mmol/L by 0.01129.
§To convert HDL-C concentration to mg/dl, divide concentration in mmol/L by 0.02586.
|| To convert FSI concentration to PU/mL, divide concentration in pmol/L by 6.
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off points, indicating that the association between TG/
HDL-C ratio and hyperinsulinemia may differ by BMI cat-
egories in that this association was stronger among people
with a lower category BMI than those with a higher BMI.
However, there was no significant interaction between the
TG/HDL-C ratio and race/ethnicity for hyperinsulinemia
by using the new cutoff point.
Discussion
Using a large and nationally representative sample, we
found that the TG/HDL-C ratio was significantly associ-
ated with FSI among nondiabetic adults of three major
racial/ethnic subpopulations in the United States: non-
Hispanic whites, non-Hispanic blacks, and Mexican
Americans. We also detected racial/ethnic differences in
predicting hyperinsulinemia, as both non-Hispanic
whites and Mexican Americans had a larger optimal cutoff
point of the TG/HDL-C ratio for the determination of
hyperinsulinemia than did non-Hispanic blacks.
The association of insulin resistance with TG/HDL-C has
been reported in overweight and obese whites [9,10].
Because the clinical samples that were used in these stud-
ies consisted primarily of white participants, the general-
izability of this association has not been established. A
recent study found that triglyceride concentration and the
TG/HDL-C ratio were not significantly associated with
insulin resistance (as determined from the insulin sensi-
tivity index) in 125 African American participants [15];
this failure to find an association between the TG/HDL-C
ratio and insulin resistance in blacks was perhaps attribut-
able to the small sample and thus a limited power to
detect associations. Our results, however, provide evi-
dence that the TG/HDL-C ratio is associated with FSI in
nondiabetic adults regardless of race/ethnicity.
Racial/ethnic differences in triglyceride concentrations,
HDL-C values, and the FSI have been widely reported
among adults and adolescents in previous studies [14,16-
19]. In the present study, non-Hispanic blacks had lower
triglyceride concentrations than non-Hispanic whites or
Mexican Americans among both men and women; for
HDL-C concentrations among males the values were high-
est among non-Hispanic blacks, but among women no
real difference was seen in this value between blacks and
whites. In both sexes the TG/HDL-C ratio was lower in
blacks than in whites or Mexican Americans. In addition,
a significant association of the TG/HDL-C ratio with insu-
lin resistance (as measured by HOMA) was stronger
among non-Africans than Africans [14], and increased
triglyceride concentrations were associated with hepatic
insulin resistance in white but not black adolescents [16].
Lipoprotein lipase activity has been found to be higher in
blacks than in whites, and this may lead to a lower triglyc-
eride concentration in blacks [29]. An elevated triglyceride
ROC curve of triglycerides (A), HDL-C (B), and the TG/HDL-C atio (C) for the prediction of hyperinsulin mia by race/ethnic tyFigure 2
ROC curve of triglycerides (A), HDL-C (B), and the TG/
HDL-C ratio (C) for the prediction of hyperinsulinemia by 
race/ethnicity. The 75th percentile cutoff value of fasting insu-















White, AUC=0.73 (95% CI, 0.70-0.79)
Black, AUC=0.72 (95% CI, 0.67-0.77)

















White, AUC=0.72 (95% CI, 0.69-0.79)
Black, AUC=0.70 (95% CI, 0.65-0.77)
















White, AUC=0.77 (95% CI, 0.74-0.79)
Black, AUC=0.75 (95% CI, 0.69-0.77)
Mexican American, AUC=0.74 (95%
CI, 0.69-0.76)
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concentration commonly causes low HDL-C values or reg-
ulates HDL-C remodeling [30-32], and thus these two
clinically useful measures may be, at least in part, causally
linked. In light of racial/ethnic differences in triglyceride
concentrations, HDL-C, and the TG/HDL-C ratio, differ-
ent cutoff points may be needed to define dyslipidemia.
In fact, use of a single cutoff value of t 150 mg/dl (or 1.69
mmol/L) for triglycerides as criteria to classify people with
dyslipidemia have led to underestimation of the preva-
lence of the metabolic syndrome in blacks as compared
with whites, particularly in men [33,34].
A TG/HDL-C ratio t 3.5 has been proposed as a cutoff
value to predict the presence of small-density LDL pheno-
type; McLaughlin and colleagues found that this cutoff
had high sensitivity (79%) and specificity (85%) in the
white population [10]. These authors also found, how-
ever, that this cutoff value had only moderate ability to
predict insulin resistance (sensitivity 47%, specificity
88%) or the metabolic syndrome (sensitivity 46%, specif-
icity 92%) [10]. We found, however, that the magnitude
of the association of hyperinsulinemia with an elevated
TG/HDL-C ratio was different when using the single cutoff
point of 3.5, suggesting that a single cutoff point may not
be applicable across diverse populations. In fact, our study
showed, for the first time, that the optimal cutoff point of
the TG/HDL-C ratio for prediction of hyperinsulinemia
was 3.0 (in mg/dL unit) for non-Hispanic whites and
Mexican Americans and 2.0 (in mg/dL unit) for non-His-
panic blacks, with reasonable sensitivity and specificity.
Applying these race/ethnicity-specific cutoff points
yielded similar magnitude of strength in the association
across racial/ethnic subgroups.
It is of great interest that the association of the TG/HDL-C
ratio with hyperinsulinemia was stronger among people
with a BMI <25 kg/m2 than those with a BMI t 30 kg/m2.
As shown in a previous study, about 16% people with
normal weight (BMI < 25 kg/m2) was identified to be
insulin resistant [35]; thus search for clinically simple and
useful biomarkers to detect insulin resistance among peo-
ple with normal weight is necessary. Although BMI, a less
expensive and convenient measure, may serve as an indi-
cator for insulin resistance among people with excessive
weight, an elevation in the TG/HDL-C ratio could be a
novel marker for hyperinsulinemia among people with
normal weight in routine clinical practice.
Our study has several strengths that deserve attention.
First, the generalizability of our results has been enhanced
by the use of a nationally representative sample. Second,
the large sample for each of the three racial/ethnic groups
enables us to empirically test differences between the
groups in the associations of the TG/HDL-C ratio with FSI.
A limitation stems from the use of FSI as a surrogate meas-
ure of insulin resistance in our data, but previous studies
have shown that fasting insulin is a valid and reliable sur-
rogate measure of insulin resistance [13]. Furthermore,
although a direct measure would theoretically be prefera-
ble, the lack of standardized insulin assay [36] greatly lim-
its the clinical utility of that approach for identifying
insulin-resistant persons. Without a standard insulin
Table 3: Prevalence, prevalence ratios, and 95% confidence intervals of hyperinsulinemia for the two TG/HDL-C ratio cutoff points by 
race and BMI categories, NHANES 1999–2002
Cutoff point of 3.5 for the TG/HDL-C ratio New cutoff point* for the TG/HDL-C ratio
Characteristic Prevalence, % Prevalence ratio (t 3.5 vs. <3.5) Prevalence, % Prevalence ratio (t cutoff vs. <cutoff)
<3.5 t 3.5 PR 95% CI <cutoff t cutoff PR 95% CI
Total 15.65 48.07 2.16 1.74 2.08 12.95 44.71 2.23 1.83 2.72
Race
Non-Hispanic White 13.0 45.6 2.3 1.7 3.1 11.3 41.9 2.3 1.8 3.0
Non-Hispanic Black 26.8 67.6 1.9 1.5 2.5 18.8 56.4 2.1 1.5 2.9
Mexican American 26.4 61.7 1.8 1.5 2.2 23.7 59.4 2.0 1.6 2.5
Interaction between race and 
TG/HDL-C ratio
F2 (2) = 5.05, P = 0.08 F2 (2) = 2.37, P = 0.31
BMI, kg/m2
< 25 3.4 14.3 3.3 1.4 7.4 2.8 13.7 3.8 1.6 8.8
25 to 29 13.3 38.2 2.9 2.0 4.2 10.5 35.8 3.4 2.4 5.0
t 30 46.1 71.4 1.5 1.3 1.8 43.6 68.0 1.5 1.3 1.7
Interaction between BMI and 
TG/HDL-C ratio
F2 (2) = 19.89, P < 0.0001 F2 (2) = 38.27, P < 0.0001
* The new cutoff point of TG/HDL-C ratio is 3.0 in mg/dL unit (1.2 in mmol/L unit) for non-Hispanic whites and Mexican Americans and 2.0 in mg/
dL unit (0.9 in mmol/L unit) for non-Hispanic blacks.
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assay, no absolute value can be developed to predict the
presence of insulin resistance across laboratories or clini-
cal settings. Thus, if one wants to use fasting insulin to
assess the state of insulin resistance, it is necessary to
develop different cut-points for every assay. In contrast,
triglyceride and HDL cholesterol concentrations are
standardized and readily available measures in routine
clinical practice. Consequently, it seems more clinically
effective to use relatively simple metabolic markers such
as the TG/HDL-C concentration ratio in the effort to iden-
tify apparently healthy people at increased risk of devel-
oping a variety of adverse clinical outcomes.
In conclusion, our findings have clinical and public
health implications. In clinical settings, the TG/HDL-C
ratio could be used as an indicator of insulin resistance
across racial/ethnic subpopulations. In large health sur-
veys, it could be used to monitor trends in cardiovascular
health in diverse populations. Our results add further sup-
port to the notion that the TG/HDL-C ratio may be a clin-
ically simple and useful indicator for insulin resistance
among nondiabetic adults regardless of race/ethnicity.
Even so, racial/ethnic-specific cutoff points of the TG/
HDL-C ratio for the determination of insulin resistance or
the risk of type 2 diabetes or cardiovascular diseases may
be needed. Future research is warranted to assess the pre-
dictive power of the TG/HDL-C ratio for the metabolic
syndrome, type 2 diabetes, or cardiovascular disease.
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